Trial reportBritish journal of cancer2002
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.
Trial report in British journal of cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01039350 (Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews · 2012Pooled it
- Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.The Cochrane database of systematic reviews · 2009Pooled it
- Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy.PharmacoEconomics · 2005Trial
- Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2004Trial
- A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.British journal of cancer · 2003Trial
- CrespFrontiers in oncology · 2025Article
- Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria.Advances in therapy · 2022Review
- Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges.Frontiers in pharmacology · 2020Review
- Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Observational
- Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Association between serum levels of C-reactive protein and response to treatment of chemotherapy-induced anemia in patients with solid tumors: a multicenter, prospective, observational study.Medical oncology (Northwood, London, England) · 2013Article
- Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2012Article
- Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Article
- Evaluation and management of fatigue in oncology: a multidimensional approach.Indian journal of palliative care · 2011Article
- Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010Article
- Darbepoetin versus epoetin alfa for the correction of anemia in cancer patients receiving radiotherapy or chemoradiotherapy treatment.Clinical medicine. Oncology · 2008Article
- Erythropoietin pharmacology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2007Review
- Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Therapeutics and clinical risk management · 2007Article
- Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Review
- Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Therapeutics and clinical risk management · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g x kg(-1) every 2 weeks or epoetin alfa, initial dose 40 000 U x wk(-1). Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.